oncosphere
EgKI-1-treated_mice
cancer_cells
significant_tumor_growth_reduction
tumor_growth_reduction_in_mice
normal_cell_growth
dose-dependent_manner
cancer_cell_growth
tumor_growth_reduction_in_EgKI-1-treated_mice
normal_cell_growth
cell_growth
tumor_growth_reduction
anti-cancer_therapeutic
oncosphere_of_canine_tapeworm_Echinococcus
oncosphere
promise_for_future_development
cancer_cell_growth
significant_tumor_growth_reduction_in_EgKI-1-treated_mice
cancer_cells
cell_cycle
oncosphere_of_tapeworm_Echinococcus
tumor_growth_reduction
oncosphere_of_canine_tapeworm_Echinococcus
oncosphere_of_tapeworm_Echinococcus
cell_apoptosis
cell_proliferation
additive_manner
tamoxifen
tamoxifen
cell_migration
ER_cancer
transcription
G2/M_phase
cell_migration
cell_cycle
single_tamoxifen
tamoxifen
co-treatment_of_tamoxifen
cell_growth_at_higher_concentrations
co-treatment
ER_cancer
death
ER_cancer
ERÎ±66
cell_migration
ER_cancer
transcription_of_cell_cycle_regulation_proteins
cell_growth_at_concentrations
co-treatment_of_tamoxifen
expression_of_mitochondrial_apoptotic_proteins
transcription_of_cell_cycle_regulation_proteins
cell_growth
G2/M_phase
tamoxifen
cell_growth_of_MCF-7_cells_at_higher_concentrations
cell_cycle
co-treatment
cell_migration
4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
patient
vary_on_voxel-basis
information_of_breast_resulting_in_detection_diagnosis_of_breast_cancer
phantom
enhancement_dynamics
perfusion_in_different_types_of_breast_lesions
breast_CT_image
vary_on_voxel-basis
vary
voxel
patient
different_types_of_breast_lesions
work
healthy_patient_into_skin_fibroglandular_tissue_adipose_tissue
voxel-basis
different_enhancement_dynamics
functional_information
example
voxel-basis
voxel-basis
perfusion_parameters
4D_breast_CT_image_acquisition
example
functional_information_of_breast_resulting_in_detection_diagnosis_of_breast_cancer_with_breast_CT.
information_of_breast_resulting
healthy_patient_into_skin_fibroglandular_tissue_adipose_tissue
breast
breast_CT.
vary
voxel-basis
expected_enhancement_of_tissues_consistent_with_given_input_parameters
breast_tissue_perfusion
voxel-basis
vary_on_voxel-basis
voxel
perfusion_parameters
information_of_breast
information_of_breast_resulting_in_detection_diagnosis_with_breast_CT.
voxel
breast_tissue_perfusion
perfusion_parameters
voxel
information_of_breast_resulting_in_detection_diagnosis
breast_tissue_perfusion
voxel-basis
perfusion_parameters_associated_with_tissue_voxel
information_of_breast_resulting_in_detection_diagnosis_of_breast_cancer_with_breast_CT.
enhancement_dynamics
breast_tissue_perfusion
information
convolution_between_arterial_input_function
cell_lines
increasing_OPAE_concentration
potent_activity_in_in-vitro_models
antioxidant_free-radical_scavenging_against_human_breast-cancer_cell_lines
activity_in_in-vitro_models
increasing_OPAE_concentration_up_to_240_g/mL
potent_activity_in_in-vitro_models
human_cell_lines
human_breast-cancer_cell_lines
human_cell_lines
increasing_OPAE_concentration
potent_activity
OPAE_concentration_up_to_240_g/mL
activity
OPAE_concentration
anticancer_activities_of_O._pallidus
OPAE_concentration_up_to_240_g/mL
free-radical_scavenging_against_human_breast-cancer_cell_lines
human_breast-cancer_cell_lines
power_activities
in-vitro_models
free-radical_scavenging
increasing_OPAE_concentration_up_to_240_g/mL
activity_in_models
OPAE_concentration
cell_lines
potent_activity_in_models
women_with_BCs_treated_from_2008_to_2017
women_with_HER2-positive_BCs_treated_with_trastuzumab_from_2008_to_2017
group_AB
nAB_regimen
women
women_with_HER2-positive_BCs_treated_with_trastuzumab
two_groups_including_196_patients
human_epidermal_growth_factor_receptor_2
nAB_regimen
women
HER2-positive_BCs_treated_from_2008_to_2017
nAB_regimen
nAB_regimen
prognosis_discussion_communication_skills
advanced_breast_cancer
advanced_breast_cancer
appointment
intervention_easy
intervention_feasibility
intervention
T-PAT_appointment
advanced_breast_cancer
breast_cancer
realistic_beliefs_about_disease_curability
planned_prognosis_discussion
appointment
utilization_of_acid_for_breast_cancer_therapy
aldehyde_dehydrogenase
utilization_for_breast_cancer_therapy_via_disruption
isolation_of_one_compound
CD44high/CD24low_subpopulation
dose-dependent_manner
cancer_prevention
isolation
expression_of_self-renewal-related_genes
isolation
ALDH
isolation
cancer_prevention
novel_utilization_of_3-O-p-coumaroyltormentic_acid_for_breast_cancer_therapy_via_disruption
isolation_of_one_compound
isolation_of_one_compound
isolation
isolation_of_one_compound
breast_cancer_cell_proliferation
phytochemicals
early-stage_breast_cancer
end_of_RT_treatment_skin_toxicity
end
15_fractions
patients
association_of_chemotherapy_with_boost
association_with_boost
terms_of_acute
excellent/good
association_of_chemotherapy
whole_breast
excellent/good
excellent/good
results_of_other_studies_published_on_association_of_hypofractionation
51.1_%_of_patients_G2
association_with_boost
excellent/good
terms
15_fractions_for_total_dose
terms_of_acute
association_of_chemotherapy
breast_cancer
terms_of_acute
phase_II_trial
VMAT-SIB_technique
breast
association_of_chemotherapy_with_boost
15_fractions_for_dose
recurrence_selection_tools
recurrence_risk_beyond_5_years
late_recurrence_selection_tools
ER-positive/human_epidermal_growth_factor_receptor_2-negative_breast_cancer
recurrence_selection_tools
treatment_cessation
patient_selection
recurrence_risk_beyond_5_years_after_diagnosis
late_recurrence_selection_tools
late_recurrence_selection_tools
recurrence_risk
late_recurrence_selection_tools
high_expression_of_estrogen-responsive_genes
recurrences
recurrence_selection_tools
recurrence_selection_tools
high_recurrence_risk_beyond_5_years_after_diagnosis
high_recurrence_risk_beyond_5_years
recurrence_risk_beyond_5_years
5_years_of_tamoxifen_therapy_with_5_years_of_tamoxifen
benefit
genes
benefit
recurrence_selection_tools
5_years_of_endocrine_therapy_reduced
late_recurrence_selection_tools
late_recurrences_in_patients_with_tumors
extended_endocrine_therapy
late_recurrences_in_patients
recurrences_occurring
benefit_from_extended_endocrine_therapy
late_recurrence_selection_tools
recurrences_in_patients
setting
estrogen-responsive_genes
genes
high_recurrence_risk
recurrences_in_patients_with_tumors
estrogen_receptor
recurrences_in_patients_with_tumors
recurrences
recurrences
recurrences_in_patients
benefit_from_extended_endocrine_therapy
genes
setting
high_recurrence_risk_beyond_5_years
high_recurrence_risk
patients_with_tumors_showing
late_recurrences_in_patients_with_tumors
recurrences
late_recurrences_in_patients
late_recurrences
recurrence_risk
late_recurrences
pathway
benefit_from_endocrine_therapy
recurrence_risk_beyond_5_years_after_diagnosis
high_recurrence_risk_beyond_5_years_after_diagnosis
recurrences
late_recurrences
recurrences_occurring
tumors_showing
recurrence_selection_tools
estrogen-responsive_genes
recurrences_occurring
benefit_from_endocrine_therapy
continue
HR_positive_breast_cancer_PI3K_inhibitors
sequencing
initiation_are_lacking
ET
development_of_generation_of_targeted_therapies_for_advanced_breast_cancer
development_of_new_generation_of_targeted_therapies_for_advanced_breast_cancer
progression_free_survival
potential_biomarkers_of_resistance
mechanisms
patients_with_hormone_receptor
initiation_of_chemotherapy_long_term_overall_survival_data_are_lacking
continue
potential_biomarkers_of_resistance
selective_estrogen_receptor_modulators
unclear
patients
backbone_in_cases
hormone_receptor
ideal_strategy
treatment_of_advanced_HR_positive_HER2_negative_breast_cancer_highlighting
initiation_of_chemotherapy_term_survival_data_are_lacking
growth_pathway
cyclin_dependent_kinase
initiation_of_chemotherapy_long_term_survival_data_are_lacking
initiation_of_chemotherapy_long_term_overall_survival_data_are_lacking
progression_free_survival
potential_biomarkers
strategy
less_toxicity
supportive_care_allowing
progression_survival
backbone_of_treatment
ideal_strategy
initiation_are_lacking
HR_positive_metastatic_breast_cancer
outcomes
supportive_care
backbone_of_treatment_in_cases
growth_pathway_in_HR_positive_breast_cancer_PI3K_inhibitors
treatment
patients_with_hormone_receptor
mechanisms
clinic
progression_survival
potential_biomarkers
initiation_of_chemotherapy_term_survival_data_are_lacking
effectiveness
women_with_breast_cancer
dysfunctional_excitement
Â±_standard_deviation_SD
women
penetration_pain
penetration_pain_desire_lubrication
46.34_Â±_8.28_years
cancer
penetration_pain
Women_'s_Sexual_Function
514_women_with_breast_cancer
dysfunctional_excitement
sexuality
breast_cancer
breast_cancer
excitement
514_women
increase_in_ERÎ±_protein_levels
ERÎ±_degradation
related_to_endocrine_therapy_resistance
development_of_tumors
related
coregulators_of_specific_protein_complexes
coactivators
endocrine_therapy_resistance
progression_of_breast_cancer
related
endocrine_therapy_resistance
ERÎ±_transcription_cycle
coactivators_for_ERÎ±
development_of_mammary_tumors
coactivators
ubiquitin_proteasome_system
ERÎ±_transcription_cycle
ERÎ±_protein_levels
related_to_therapy_resistance
development
coactivators_for_ERÎ±
related_to_therapy_resistance
ERÎ±_degradation
development_of_mammary_tumors
estradiol_hormone
development
therapy_resistance
ubiquitin_proteasome_system
related_to_endocrine_therapy_resistance
ERÎ±
OBCS
investigation
Objective_Breast_Cosmesis_Scale
adjuvant_partial_breast_irradiation
further_investigation
breast_irradiation
patient
partial_breast_irradiation
further_investigation_in_future_studies
investigation_in_future_studies
changes
nonstandardized_photographs
breast-conserving_surgery
adjuvant_breast_irradiation
further_investigation
accelerated_partial_breast_irradiation
patient
adjuvant_accelerated_breast_irradiation
breast_cosmesis
investigation
trainees
surgery
changes_in_breast_cosmesis
treatment
treatment
further_investigation_in_future_studies
adjuvant_accelerated_partial_breast_irradiation
interstitial_fractionated_high-dose-rate_brachytherapy
brachytherapy
future_studies
nanomolar_dose
distinct_antagonism
MTT
continued_presence
aspects_of_malignant_phenotype
several_aspects
pivotal_role_of_IR_antagonist_S961
even_presence_of_insulin
role_of_IR_antagonist_S961
role_of_IR_antagonist_S961_on_IR_signalling_in_MCF-7_MDA-MB-231
presence_of_S961
proliferation_in_breast_tumour_cells
role_on_IR_signalling_in_MCF-7_MDA-MB-231
role_on_IR_signalling
pivotal_role_of_IR_antagonist_S961_on_IR_signalling
IR-A_isoform
breast_carcinoma_cells
several_aspects_of_malignant_phenotype_including_cell_proliferation
IR-A_isoform
expression_of_IRs
role_of_IR_antagonist_S961_on_IR_signalling
continued_presence_of_S961
breast_cancer_pathogenesis
several_aspects_of_malignant_phenotype_including_cell_proliferation
pivotal_role_on_IR_signalling
breast_cancer_pathogenesis
IRs
cellular_proliferation_in_breast_tumour_cells
proliferation_owing
several_aspects_of_malignant_phenotype
growth
quantitative_PCR
presence_of_S961
aspects_of_phenotype_including_cell_proliferation
breast_tumour_cells
IRs
IR_overexpression
continued_presence_of_S961
antagonism
expression_of_IRs
IRs
several_aspects_of_phenotype_including_cell_proliferation
pivotal_role_on_IR_signalling_in_MCF-7_MDA-MB-231
breast_cancer_pathogenesis
extensive_growth
aspects_of_malignant_phenotype_including_cell_proliferation
pivotal_role_of_IR_antagonist_S961_on_IR_signalling_in_MCF-7_MDA-MB-231
presence
cellular_proliferation_in_breast_tumour_cells
several_aspects_of_phenotype
MCF-7_MDA-MB-231
continued_presence
IR_overexpression
study_2
approximately_3_years
decline
Pearson_'s_correlation_coefficient
cognitive_decline
WMS-R_indices_between_two_studies
plasma_IL-6_levels
breast_cancer_patients
unclear
breast_conservation_therapy
study_2
study_2
approximately_3_years
study_2
three_different_metrics_of_mortality
NF-ÎºB/SOX4_activation
mouse
reduction_in_breast_cancer_growth
investigation
breast_cancer_growth
investigation
responsive_gene
highest_responsive_gene
CXCL1_administration
further_investigation
investigation
reduction
highest_responsive_gene
loop_TAMs
breast_cancer_lymph_node_metastasis
breast_cancer_metastasis
CXCL1_administration
investigation
highest_gene
investigation
gene
loop
investigation
significant_reduction_in_breast_cancer_growth
investigation
further_investigation
its_transcription
further_investigation
further_investigation
SOX4_promoter
further_investigation
responsive_gene
breast_cancer_lymph_node_metastasis
further_investigation
further_investigation
TAMs
loop_TAMs
breast_cancer_lymph_node_metastasis
highest_gene
breast_cancer_lymph_node_metastasis
investigation
Level_0_doses
Level_1_doses
Grade_3_oral_mucositis
advanced_recurrent_breast_cancer
Level_1_doses
GEM
combination_with_other_chemotherapeutic_agents
Level_0_doses
Grade_3_oral_mucositis
Level_1
Level_0
ERI
only_1_patient_of_Level_1_group
metastatic_breast_cancer
ERI
Japanese_patients_with_metastatic_breast_cancer
Level_1_doses
closed_loop_structure
cancer-related_death